02348 DAWNRAYS PHARMA
Closed Add to PorfolioKey Financial Ratio (Fiscal Year: 12/2023) | |||
Current | 2.57X | Oper Margin | 39.6% |
---|---|---|---|
LT Debt/Equity | N/A | Net Margin | 28.3% |
Total Debt/Equity | 4.2% | Return on Equity | 11.4% |
Price/Book | 0.56X | Return on Assets | 9.0% |
(HKD 1.170) | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
Net Profit (MHKD) | 359.32 | 401.45 | 438.08 | 318.22 | 285.55 |
---|---|---|---|---|---|
Net Profit Growth (%) | -10.5 | -8.4 | +37.7 | +11.4 | -17.5 |
Earnings Per Share (HKD) | 0.24 | 0.268 | 0.293 | 0.206 | 0.181 |
Earnings Per Share Growth (%) | -10.6 | -8.4 | +42.0 | +13.6 | -16.9 |
Dividend Per Share (HKD) | 0.080 | 0.088 | 0.080 | 0.115 | 0.058 |
P/E* (X) | 4.88 | 4.37 | 4.00 | 5.68 | 6.45 |
Yield (%) | 6.84 | 7.52 | 6.84 | 9.83 | 4.96 |
Dividend Share (%) | 33.39 | 32.85 | 27.35 | 55.83 | 31.99 |
Book NAV (HKD) | 2.097 | 1.976 | 1.943 | 1.700 | 1.455 |
Auditors' Opinion | N/A | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2024-03-28 21:40:23
Latest Result
(RMBMn) | 2023-12 | 2022-12 | Chg* (%) | 2021-12 |
Cover Period (mths) | 12 | 12 | NA | 12 |
---|---|---|---|---|
Turnover | 1,151 | 1,278 | -9.9 | 1,165 |
Operating Result | 454.99 | 460.643 | -1.2 | 386.672 |
Associates | -40.933 | -61.905 | -33.9 | -46.418 |
Profit Before Taxation | 414.057 | 438.408 | -5.6 | 439.323 |
Taxation | 91.39 | 82.557 | +10.7 | 85.16 |
Profit /( Loss) After Taxation | 322.667 | 355.851 | -9.3 | 354.163 |
Minority Interests | -3.333 | -2.206 | +51.1 | -4.012 |
Net Profit | 326 | 358.057 | -9.0 | 358.175 |
Earnings Per Share () | 0.2396 | 0.2679 | -10.6 | 0.2925 |
Dividend Per Share () | 0.0800 | 0.0880 | -9.1 | 0.0800 |
Announcement Date | 2024-03-22 | 2023-03-26 | NA | 2022-03-27 |
* Annualised
Last Update Time: 2024-03-28 21:40:28